Chemistry:PZKKN-94

From HandWiki

PZKKN-94 is a dual serotonin 5-HT1B receptor agonist and serotonin 5-HT6 receptor antagonist which is under investigation for the potential treatment of Parkinson's disease.[1] Its values were 39 nM (EC50) and 88.1% (Emax) at the serotonin 5-HT1B receptor and 7.7 nM (KB) at the serotonin 5-HT6 receptor.[1] The drug showed selectivity for these receptors over 43 other targets.[1] It shows favorable drug-like properties.[1] In rodents, PZKKN-94 shows antiparkinsonian-like, pro-cognitive, and antidepressant-like effects.[1] PZKNN-94 was first described in the scientific literature by Paweł Zajdel and colleagues in 2025.[1]

See also

  • List of investigational Parkinson's disease drugs

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 "Simultaneous 5-HT1BR agonist/5-HT6R antagonist action as a potential treatment of Parkinson's disease and its comorbidities". The Journal of Pharmacology and Experimental Therapeutics 392 (2). February 2025. doi:10.1016/j.jpet.2024.100055. PMID 40023605. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:PZKKN-94&oldid=4030952"